Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
Semaglutide is showing impressive results for weight loss in clozapine patients — up to 13.9% body weight reduction — but experts are sounding the alarm about a potentially deadly interaction. Both drugs slow gut motility, and clozapine's most lethal side effect is bowel obstruction. With little long-term safety data and trials too short to catch delayed harms, clinicians are navigating largely uncharted territory.
Semaglutide is delivering remarkable weight loss for patients on clozapine — a population that routinely gains 20–30 kg on the antipsychotic — with the COaST trial reporting a 13.9% body weight reduction over 36 weeks and a meta-analysis showing an average 11 kg loss across 258 patients. That's roughly four times what metformin achieves in this group. But experts are raising urgent safety concerns about combining two drugs that both slow gut motility.
Clozapine's most lethal side effect isn't agranulocytosis or myocarditis — it's gastrointestinal hypomotility, which can progress to paralytic ileus, bowel rupture, and death. GLP-1s slow the gut too, and the synergistic risk of combining them remains largely unstudied. Compounding the problem: clozapine blunts visceral sensitivity, meaning patients often don't feel — and don't report — constipation, making self-reported outcomes in trials unreliable.
Key Takeaways:
Why it matters: The combination of GLP-1s and clozapine is already becoming more common in clinical practice, yet the safety data to guide prescribers barely exist. Without objective GI monitoring and better-designed trials, a preventable — and potentially fatal — harm could go undetected for years.
